Clinical Trial Update: Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years [Phase 2, Phase 3]

View source ↗

Summary

Pfizer's TICOVAC was evaluated in healthy children aged 6 months to 3 years across Phase 2/3 for safety and immunogenicity after three vaccinations; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• TicoVac (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 2, Phase 3 | Status: COMPLETED